Insights On Upstream Manufacturing

  1. Scale Up Or Scale Out? Choosing An Adherent Cell Culture Platform 4/21/2026

    Facility space costs up to $1,000/sq ft and planning timelines stretch 18 months, making your adherent cell culture platform choice one of the highest-stakes decisions in vaccine manufacturing scale-up.

  2. Aligning Upstream And Downstream Development (Part 1) 4/20/2026

    In this episode of “Better Biopharma,” panelists from the Bioprocess Online Live event “Optimizing Process Development Through Upstream And Downstream Integration” continue their conversation about how upstream and downstream development teams can work together to accelerate timelines and reduce risks and bottlenecks in process development.

  3. Where Sourcing Meets Science: Smarter Collaboration, Better Outcomes 4/20/2026

    See how collaboration-driven raw material control reduces variability, improves cell culture performance, and delivers measurable cost and productivity gains in biotherapeutic manufacturing.

  4. What To Look For In A Cell Culture Media Supplier 4/17/2026

    Choosing a cell culture media supplier is crucial in biopharmaceutical manufacturing. Explore five key factors to take into account when choosing a supplier and evaluating their capabilities.

  5. Automated T Cell Manufacturing From Start To Fill 4/17/2026

    Gain insight into how an automated, closed workflow can integrate T cell enrichment, activation, transduction, expansion, and formulation across fresh and frozen starting materials.

  6. CAR T Cell Generation From Cryopreserved Leukapheresis Products 4/17/2026

    A seven‑day CAR T cell manufacturing workflow shows how cryopreserved leukapheresis material can deliver high viability and strong antitumor activity, offering a more flexible path for production.

  7. How To Select The Right Platform For Your Vaccine Production Process 4/16/2026

    Evaluate surface treatments, scalability, and contamination risks to select the right adherent platform. Testing early ensures a seamless transition from benchtop to production.

  8. Maximizing Performance And Quality In Fed-Batch And Perfusion-Based IgG Productions Customer Interview 4/16/2026

    From lab to production scale: a researcher's firsthand account of what bioreactor scaling and high-density perfusion really demand in practice.

  9. How MacroGenics Increased mAb Titers By Up To 80% In Scale-Up 4/16/2026

    Learn how a structured, scalable approach to process development can help improve productivity, maintain product quality, and support a smoother transition to manufacturing.

  10. Industrializing Cell Therapy With Perfusion 4/14/2026

    Explore how intensified perfusion strategies enable rapid, high‑density CAR‑T expansion, predictive scale‑down modeling, and efficient automated harvest, supporting shorter timelines and higher yields.